Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is...
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023...
If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of DilationFARMINGTON HILLS, Mich.,...
-- Board and Management Team to Answer Shareholder Questions -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE)...
MINNEAPOLIS, Feb. 13, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company...
PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board DirectorBURLINGTON, Mass. and JERUSALEM, Feb....
Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with...
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory...
DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing...
BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”),...
NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused...
Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated...
$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions...
- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration...
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...
All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate...
IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused...
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in...